Encoded lays off 29% of staff to fund Dravet syndrome gene therapy trial
Encoded Therapeutics is shrinking its headcount by 29% as the gene therapy biotech draws resources away from its early-stage R&D to focus resources on its Dravet syndrome program.
Encoded Therapeutics is shrinking its headcount by 29% as the gene therapy biotech draws resources away from its early-stage R&D to focus resources on its Dravet syndrome program.
